A committee from the European Medicines Agency (EMA) recommended that AstraZeneca‘s triple combination therapy Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) be approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The recommendation, from the EMA’s Committee for Medicinal Products for…
Exposure to cigarette smoke during pregnancy impairs lung embryonic development, which may increase the baby’s later-in-life risk for disorders like chronic obstructive pulmonary disease (COPD), a mouse study suggests. Smoke was found to increase the levels of the amphiregulin (AREG) protein, which may impair the formation of certain…
The use of face masks does not cause intoxication induced by exhaled carbon dioxide (CO2), even in people with lung function impairment such as those with chronic obstructive pulmonary disease (COPD), a study reports. The study, “Effect of Face Masks on Gas Exchange in Healthy Persons and Patients…
Older patients with chronic obstructive pulmonary disease (COPD) taking oral, synthetically-made cannabinoids — medications based on compounds found naturally in marijuana (the plant Cannabis sativa) — to manage some of their symptoms have a 64% higher risk of death compared to those not taking the medications, according to…
The American Thoracic Society (ATS), through its Research Program and with support from 4DMedical, announced it will award three, $50,000 grants for research using a new, non-invasive technology to assess lung health. These one-year grant opportunities are focused on work into chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary…
The COPD Foundation has launched the COPD360Net project to facilitate, assess, and accelerate clinical trials to further the development and approval of novel digital health tools and treatments for chronic obstructive pulmonary disease (COPD). The project is being launched before November, which is COPD Awareness Month,…
Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — called ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) — are each expected to enroll up to 800 patients…
Chronic obstructive pulmonary disease (COPD) is more prevalent than previously thought and associated with a mortality rate that is likely higher than earlier estimates, a review study has found. Invasive aspergillosis — a respiratory infection caused by molds belonging to the Aspergillus genus — may be a…
PAO Group and Puration have entered a new agreement that will allow PAO Group to build a proprietary hemp cultivar development facility on Puration’s branded site in Farmersville, Texas, according to a press release. The new facility is expected to help provide materials to further the development of…
Nebulized ensifentrine (RPL554) — which works both to widen the airways and as an anti-inflammatory — showed a significant early effect on breathlessness in people with chronic obstructive pulmonary disease (COPD), according to the therapy’s developer, Verona Pharma. Apart from easing breathlessness, in four weeks of treatment…
Get regular updates to your inbox.